Arbutus Biopharma Corporation

Arbutus Biopharma Corporation is a publicly traded biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B virus (HBV) infection. With an experienced team and a strong pipeline of innovative therapeutic candidates, Arbutus aims to transform the lives of millions affected by this devastating disease. The company's research focuses on advancing a range of drug candidates, including RNA interference (RNAi) -based therapeutics, gene editing technologies, and combination therapies.